FDA Approves Belzutifan for Treatment of Locally Advanced, Unresectable, or Metastatic Pheochromocytoma and Paraganglioma

Source: Pharmacy Times articles

The FDA approves belzutifan, the first oral treatment for pheochromocytoma and paraganglioma, offering a new treatment pathway for patients with these rare tumors.
Read More